Aligos Therapeutics (ALGS) EBIT (2019 - 2026)
Aligos Therapeutics (ALGS) reported EBIT of -$26.9 million for Q1 2026, down 39.94% on a YoY basis from -$44.8 million in Q1 2025, and down 144.03% quarter-over-quarter from $61.2 million in Q4 2025.
Aligos Therapeutics (ALGS) EBIT (2019 - 2026) Analysis & Trends
Aligos Therapeutics has reported EBIT for 8 years, with the latest figure at -$26.9 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 39.94% year-over-year to -$26.9 million; the trailing twelve-month figure through Mar 2026 stood at -$12.7 million (up 85.29% YoY), and the FY2025 full-year result was -$5.0 million, up 94.37% from the prior year.
- EBIT for Q1 2026 stood at -$26.9 million, down from $61.2 million in the prior quarter.
- The five-year high for EBIT was $61.2 million in Q4 2025, with the low at -$35.6 million in Q1 2022.
- Historically, EBIT has averaged -$18.0 million across 5 years, with a median of -$20.6 million in 2024.
- The largest YoY upside for EBIT was 397.41% in 2025 against a maximum downside of 40.88% in 2025.
- Aligos Therapeutics' EBIT stood at -$22.7 million in 2022, then fell by 14.62% to -$26.0 million in 2023, then increased by 20.9% to -$20.6 million in 2024, then jumped by 397.41% to $61.2 million in 2025, then sank by 144.03% to -$26.9 million in 2026.
- The last three EBIT figures came in at -$26.9 million (Q1 2026), $61.2 million (Q4 2025), and -$28.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -15.76 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -65.83 Mn |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -26.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.93 Mn |
| Dec 31, 2025 | 61.16 Mn |
| Sep 30, 2025 | -28.36 Mn |
| Jun 30, 2025 | -18.57 Mn |
| Mar 31, 2025 | -19.24 Mn |
| Dec 31, 2024 | -20.56 Mn |
| Sep 30, 2024 | -20.13 Mn |
| Jun 30, 2024 | -26.41 Mn |
| Mar 31, 2024 | -22.05 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Sep 30, 2023 | -19.07 Mn |
| Jun 30, 2023 | -19.14 Mn |
| Mar 31, 2023 | -23.92 Mn |
| Dec 31, 2022 | -22.68 Mn |
| Sep 30, 2022 | -18.95 Mn |
| Jun 30, 2022 | -20.39 Mn |
| Mar 31, 2022 | -35.56 Mn |
| Dec 31, 2021 | -37.95 Mn |
| Sep 30, 2021 | -33.07 Mn |
| Jun 30, 2021 | -29.57 Mn |